Central & South Asia
India ruling on cancer drug to be challenged
Order forcing Bayer to license its product to local company has huge repercussions for pharmaceutical giants.
Last Modified: 15 Mar 2012 04:50

A patent ruling in India is forcing German drug giant Bayer to license its anti-cancer medicine to an Indian company, Natco.

This will slash the price of the drug in India by up to 97 per cent. Bayer insists it will fight the ruling although Natco will be paying it six per cent royalty on the sales of Nexavar.

This is the first time such a ruling has been made in India and has massive repercussions for drug giants and their patents globally.

Prerna Suri reports from New Delhi.

Al Jazeera
Topics in this article
Featured on Al Jazeera
An innovative rehabilitation programme offers Danish fighters in Syria an escape route and help without prosecution.
Street tension between radical Muslims and Holland's hard right rises, as Islamic State anxiety grows.
Take an immersive look at the challenges facing the war-torn country as US troops begin their withdrawal.
Ministers and MPs caught on camera sleeping through important speeches have sparked criticism that they are not working.
Anti-government secrecy organisation struggling for relevance without Julian Assange at the helm.
After decades of overfishing, Japan is taking aim at increasing the number of bluefin tuna in the ocean.
Chinese scientists are designing a particle-smashing collider so massive it could encircle a city.
Critics say the government is going full-steam ahead on economic recovery at the expense of human rights.
Spirits are high in Scotland's 'Whisky Capital of the World' with one distillery thirsty for independence.
join our mailing list